OncoHealth

Join us at #AMCPNexus as Laura Bobolts, PharmD, BCOP, SVP of Clinical Strategy and Growth, explores the transformative impact of precision medicine and biomarkers on oncology care. Don't miss the chance to learn from a leading expert in the field! https://hubs.la/Q02S-Ym-0

Discover how five clinical trials can immediately change the way we treat patients with breast cancer, lung cancer, and melanoma. These trials are paving the way for advancements in cancer treatments, helping to deliver the best, most cost-effective care for your members. https://hubs.la/Q02Ql_Tj0

Join OncoHealth for a post-AMCP Nexus Happy Hour at the Hard Rock Café in Las Vegas! Relax after a busy conference day with cocktails, snacks, and great company. Don't forget to RSVP to save your spot—we can’t wait to see you there! https://hubs.la/Q02PKF670

Register today: https://hubs.la/Q02N4jbh0 Oncology costs are rising and engaging your oncology providers and developing partnerships is more difficult than ever. Join us, and hear from OncoHealth's Andrew Norden, MD, Chief Medical Officer and Melissa Pozotrigo, PharmD, BCOP, Senior Clinical Pharmacy Oncologist, as they address the rapidly changing drug ecosystem and how to work more effectively with your oncology providers.

OncoHealth is proud to announce that it has been awarded a 2024 Gold Bell Seal for Workplace Mental Health by Mental Health America. The Bell Seal is a first-of-its-kind workplace mental health certification recognizing employers striving to create mentally healthy workplaces for their employees.   The Bell Seal recognizes employer advances in workplace mental health by awarding Bronze, Silver, Gold, and Platinum recognition levels. Only 1 in 4 employers meet the standards for Bell Seal certification. OncoHealth underwent a rigorous evaluation of its policies and practices in four areas: workplace culture, benefits, compliance, and wellness programs. Gaining status as a Bell Seal-certified organization demonstrates its ongoing commitment to employee mental health and well-being. Shay Hurst, Chief People Officer, added, “We are thrilled to receive this recognition based on our practices and commitment to creating a mentally healthy workplace. Employee wellbeing continues to be an important part of our culture, as it is for the patients we serve.”   OncoHealth is committed to supporting its employees and looks forward to continuing work to ensure they uphold the standards the Bell Seal for Workplace Mental Health.   Learn more about MHA and the Bell Seal for Workplace Mental Health at https://lnkd.in/dCM9CdX

Gain exclusive insights from Dr. Laura Bobolts, PharmD, BCOP, Senior Vice President of Clinical Strategy and Growth at OncoHealth as she summarizes pivotal #ASCO24 presentations on key clinical trials that could reshape treatment approaches for patients with breast cancer, lung cancer, and melanoma. Don't miss out - register here! https://lnkd.in/gX9hXh46

We’ve got you covered with all the essentials for your night out in Vegas. Come pick up your Preparedness Kit in Booth #1637 - you’ll thank us later!

3️⃣ More studies that caught my 👀 as #ASCO2024 comes to an end… —1️⃣— Plenary session found palliative care delivered via telehealth was as effective as in-person care in maintaining quality of life! 🔹 Quality of life at 24 weeks in advanced lung cancer patients scored 99.67 for digital care vs 97.67 for in-person care, via the FACT-L score 🔹 👉 “If there is one message for practices after getting back from the ASCO meeting, it is to reflect on when and how they are currently delivering ✨virtual care✨and what the opportunities for improvement may be.”👈 Dr. Monika K Krzyzanowska via ASCO Daily News —2️⃣— IMROZ: Isatuximab + VRd (bortezomib, lenalidomide, dex) reduces the risk of progression or death by 40% over VRd in newly diagnosed transplant INeligible multiple myeloma. 🔹 Isatuximab (Sarclisa) + VRd expected to get FDA approved by Sept 27th BUT the trial is published now, full text in the New England Journal of Medicine, supporting off-label insurance coverage for many per CMS —3️⃣— ASC4FIRST: Asciminib demonstrated ✨superiority in newly diagnosed CML (chronic myeloid leukemia)✨over standard of care TKI (imatinib, dasatinib, nilotinib, bosutinib) with improved major molecular response rates at week 48 (67.7% vs 49.0%) with less toxicity. 🔹 Asciminib (Scemblix) received Breakthrough Therapy designation for 1st line use May 2024, priority review status likely to follow 🔹 This trial is published in full text in the New England Journal of Medicine now, supporting off-label insurance coverage for many per CMS ❓Wonder what my top top tippity top favorite studies were from #ASCO❓Stay tuned for more!! - Laura Bobolts, PharmD, BCOP What was your✨top✨favorite #ASCO study❓ #ASCO #Cancer #DigitalHealth #Scemblix #Sarclisa #OncoHealth

Ready for more #ASCO2024 data, hot off the press like hot cakes 🥞(can you tell I’m hungry?) Laura Bobolts, PharmD, BCOP here reporting from the biggest cancer conference in the world! PALMARES-2, an Italian study evaluating the real world efficacy of CDK4/6 inhibitors + endocrine tx in HR+/HER2- metastatic breast cancer (MBC) 👉 Abemaciclib (Verzenio) or Ribociclib (Kisqali) use improved progression-free survival vs Palbociclib (Ibrance) but no significant difference btw Abema compared to Ribo. Many payers prefer Abemaciclib or Ribociclib over Palbociclib today… but they need to be ready for Inavolisib to shake things up! Inavolisib is likely to get FDA approval before Nov 27th in combo w/ ✨Palbociclib✨& Fulvestrant in PIK3CA-mutated, HR+/HER2- MBC w/ recurrence after adjuvant endocrine tx 👉57%⬇️🎉 in the risk of progression or death. Since Inavolisib was only studied w/ Palbo & not Ribo or Abema, payers may need to revisit their strategies in this PIK3CAm population. #ASCO #breastcancer #CDK46inhibitors #Ibrance #Kisqali #Verznio

It’s getting wild at #ASCO - 3 people standing ovation in the middle of the ADRIATIC trial! Durvalumab (Infinzi) consolidation is a 🎉new standard of care🎉 in limited stage SMALL cell lung cancer (SCLC) following chemoradiotherapy, adding✨22.5 months✨of life to patients in this cancer well known to rapidly progress to an incurable stage. Key points: ✨Median overall survival: 55.9 months with durvalumab vs 33.4 mo with placebo (HR=0.73) ✨ADRIATIC is the 1st positive phase 3 immunotherapy trial in limited stage SCLC!!! ✨Durvalumab consolidation is given for a MAX of 2 years in limited stage SCLC ✨ADRIATIC trial is not published in full-text yet (keep your eye out!), not in NCCN yet either - given this, CMS doesn’t broadly support off-label coverage. This could be case by case. Data changes too fast in oncology! What do you think about this one? 1st targeted therapy for limited stage SCLC! #ASCO #ADRIATIC #Imfinzi #lungcancer #oncohealth